Research analysts at Craig Hallum started coverage on shares of Alterity Therapeutics (NASDAQ:ATHE – Get Free Report) in a research note issued to investors on Tuesday. Get Alterity Therapeutics alerts:Read Our Latest Report on Alterity TherapeuticsAlterity Therapeutics Price PerformanceInstitutional Investors Weigh In On Alterity TherapeuticsShares of Alterity Therapeutics stock opened at $4.58 on Tuesday. A hedge fund recently bought a new position in Alterity Therapeutics stock. Alterity Therapeutics Company Profile(Get Free Report)Alterity Therapeutics is a clinical-stage biotechnology company focused on the development of novel treatments for neurological and neurodegenerative disorders. Read MoreReceive News & Ratings for Alterity Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alterity Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.